Pfizer Announces New Chief Oncology Officer

New York, February 5, 2025 – Pfizer Inc. (NYSE: PFE) today announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr. Legos will be responsible for leading the company’s Oncology Research & Development, overseeing all functions from pre-clinical to late-stage clinical development activities. Dr. Legos will report to Chris Boshoff, M.D., PhD, Chief Scientific Officer and President, Pfizer Research & Development, and will represent Oncology on Pfizer’s R&D Leadership Team. Dr. Legos will succeed Roger Dansey, M.D., Interim Chief Oncology Officer, who will transition to retirement as previously communicated.  

Dr. Legos has a proven track record of more than 20 years of experience successfully leading large multinational teams across all functions and stages of Oncology drug development, which has resulted in more than 40 global regulatory drug and companion diagnostic approvals, including new molecular entities, product line extensions, and premarket approvals for devices.

Dr. Legos will join Pfizer from Novartis, where he serves as Executive Vice President and Global Head of Oncology and Hematology Development. Prior to joining Novartis in 2015, Dr. Legos served as Vice President and Global Medicines Development Leader in Oncology at GlaxoSmithKline (GSK). He also previously held senior leadership positions in clinical development, translational medicine, and was the head of Oncology Strategy, where he was instrumental in the creation and growth of the GSK Oncology Business Unit.

Dr. Legos earned his PhD in physiology from Temple University School of Medicine, an MBA in Finance from the Villanova University School of Business and completed his post-graduate fellowship training in pharmacology and pharmaceutical medicine. He is an author of more than 40 manuscripts and numerous abstracts published in peer-reviewed journals and serves as a scientific advisor to the Melanoma Research Alliance, a Strategic Advisory Board member for Gingko Bioworks. Dr. Legos also currently represents Novartis as key expert advisor on several industry-wide Oncology Task Forces for Friends of Cancer Research (FOCR), LUNGevity, and Bloomberg New Economy.

About Pfizer Oncology
At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice
The information contained in this release is as of February 5, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking statements about Pfizer Oncology, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s product candidates; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Media Contact:
+1 (212) 733-1226
[email protected]  

Investor Contact:    
+1 (212) 733-4848
[email protected]